Amyloid-β (Aβ) is generated from amyloid-β protein precursor (AβPP) via secretase enzymes. While AβPP processing and its localization are well understood, the function of AβPP is largely unknown. AβPP has been shown to localize to mitochondria, but the consequence of this is not understood.
Objective
We examined the consequences of modulating mitochondrial AβPP content on mitochondrial function.
Methods
We measured mitochondrial AβPP localization in postmortem human brain from non-demented and AD subjects. To understand the effects of mitochondrial localization of AβPP on mitochondria, we leveraged AβPP constructs with increased (D23A) or decreased (3 M) mitochondrial localization compared to a wild-type (WT) construct. We measured mitochondrial function including dynamics and mitophagy.
Results
We observed increased AβPP mitochondrial localization in postmortem brain of sporadic AD subjects. Increased or decreased mitochondrial AβPP content led to reduced electron transport chain (ETC) activities, reduced ATP levels, increased mitochondrial superoxide production, hyperpolarized mitochondrial membrane potential, and increased mitochondrial calcium content. Reduced mitochondrial AβPP content reduced mitophagy flux, while increased mitochondrial AβPP content increased mitophagy flux. Increased or decreased mitochondrial AβPP content reduced mitochondrial biogenesis. We identified interactions between AβPP and mitophagy/autophagy proteins. We next examined if a specific motif in AβPP was responsible for alterations in mitochondrial function and mitophagy. Mitophagy flux was inhibited with expression of ΔCT AβPP, suggesting a role for the C-terminus of AβPP in mitophagy induction.
Conclusions
Overall, these findings highlight a critical role of AβPP in mitochondrial physiology. Alterations to AβPP mitochondrial content can lead to mitochondrial dysfunction.
MurphyMPLeVineH3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis2010; 19: 311–323.
2.
HanXJHuYYYangZJ, et al.Amyloid beta-42 induces neuronal apoptosis by targeting mitochondria. Mol Med Rep2017; 16: 4521–4528.
3.
WilkinsHMSwerdlowRH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull2017; 133: 71–79.
4.
O'BrienRJWongPC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci2011; 34: 185–204.
5.
LeeJHLauKFPerkintonMS, et al.The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem2003; 278: 47025–47029.
6.
Morais CardosoSSwerdlowRHOliveiraCR. Induction of cytochrome c-mediated apoptosis by amyloid beta 25–35 requires functional mitochondria. Brain Res2002; 931: 117–125.
7.
AnandatheerthavaradaHKBiswasGRobinMA, et al.Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol2003; 161: 41–54.
8.
FukuiHDiazFGarciaS, et al.Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A2007; 104: 14163–14168.
9.
WilkinsHMTroutwineBRMentaBW, et al.Mitochondrial membrane potential influences amyloid-beta protein precursor localization and amyloid-beta secretion. J Alzheimers Dis2022; 85: 381–394.
10.
Duran-AniotzCMoralesRMoreno-GonzalezI, et al.Brains from non-Alzheimer's individuals containing amyloid deposits accelerate Abeta deposition in vivo. Acta Neuropathol Commun2013; 1: 76.
11.
JiaKTianJWangT, et al.Mitochondria-sequestered Abeta renders synaptic mitochondria vulnerable in the elderly with a risk of Alzheimer disease. JCI Insight2023; 8: e174290.
12.
TroutwineBRStropeTAFranczakE, et al.Mitochondrial function and Abeta in Alzheimer's disease postmortem brain. Neurobiol Dis2022; 171: 105781.
13.
AlghusenIMCarmanMSWilkinsHM, et al.O-GlcNAc impacts mitophagy via the PINK1-dependent pathway. Front Aging Neurosci2024; 16: 1387931.
14.
FisarZHansikovaHKrizovaJ, et al.Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer's disease and depressive disorder. Mitochondrion2019; 48: 67–77.
15.
FisarZHroudovaJHansikovaH, et al.Mitochondrial respiration in the platelets of patients with Alzheimer's disease. Curr Alzheimer Res2016; 13: 930–941.
16.
GuoLTianJDuH. Mitochondrial dysfunction and synaptic transmission failure in Alzheimer's disease. J Alzheimers Dis2017; 57: 1071–1086.
17.
KerrJSAdriaanseBAGreigNH, et al.Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci2017; 40: 151–166.
18.
KishSJBergeronCRajputA, et al.Brain cytochrome oxidase in Alzheimer's disease. J Neurochem1992; 59: 776–779.
19.
Martin-MaestroPGarginiRGarciaE, et al.Mitophagy failure in APP and tau overexpression model of Alzheimer's disease. J Alzheimers Dis2019; 70: 525–540.
20.
PrydeKRSmithHLChauKY, et al.PINK1 Disables the anti-fission machinery to segregate damaged mitochondria for mitophagy. J Cell Biol2016; 213: 163–171.
21.
LiuSSawadaTLeeS, et al.Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet2012; 8: e1002537.
22.
MijaljicaDPrescottMDevenishRJ. Mitophagy and mitoptosis in disease processes. Methods Mol Biol2010; 648: 93–106.
23.
FangEF. Mitophagy and NAD(+) inhibit Alzheimer disease. Autophagy2019; 15: 1112–1114.
24.
FangEFHouYLautrupS, et al.NAD(+) augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat Commun2019; 10: 5284.
25.
FangEFHouYPalikarasK, et al.Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci2019; 22: 401–412.
26.
FangEFWaltzTBKassahunH, et al.Tomatidine enhances lifespan and healthspan in C. elegans through mitophagy induction via the SKN-1/Nrf2 pathway. Sci Rep2017; 7: 46208.
27.
FengDLiuLZhuY, et al.Molecular signaling toward mitophagy and its physiological significance. Exp Cell Res2013; 319: 1697–1705.
28.
DoodyRSRamanRFarlowM, et al.A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med2013; 369: 341–350.
29.
GalaskoDRGraff-RadfordNMayS, et al.Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord2007; 21: 292–299.
30.
HopkinsCR. ACS Chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic. ACS Chem Neurosci2011; 2: 279–280.
31.
SperlingRSallowaySBrooksDJ, et al.Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol2012; 11: 241–249.
32.
MintunMALoACDuggan EvansC, et al.Donanemab in early Alzheimer's disease. N Engl J Med2021; 384: 1691–1704.
33.
SwansonCJZhangYDhaddaS, et al.A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther2021; 13: 80.
34.
Neuropathology Steering Committee. Coding guidebook for the NACC neuropathology data form. 11th ed. Seattle, WA: Springer Science Business Media and Elsevier, 2020.
35.
Young-PearseTLBaiJChangR, et al.A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci2007; 27: 14459–14469.
36.
MaYTaylorSS. A molecular switch for targeting between endoplasmic reticulum (ER) and mitochondria: conversion of a mitochondria-targeting element into an ER-targeting signal in DAKAP1. J Biol Chem2008; 283: 11743–11751.
37.
MontesinosJArea-GomezE. Isolation of mitochondria-associated ER membranes. Methods Cell Biol2020; 155: 33–44.
38.
MaXDingWX. A fluorescence imaging based-assay to monitor mitophagy in cultured hepatocytes and mouse liver. Liver Res2021; 5: 16–20.
39.
MaXDingWX. Methods for monitoring mitochondrial biogenesis and turnover in cultured hepatocytes and mouse liver using MitoTimer Reporter Assay. Methods Mol Biol2023; 2675: 97–107.
40.
DeviLPrabhuBMGalatiDF, et al.Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci2006; 26: 9057–9068.
41.
YangTTHsuCTKuoYM. Amyloid precursor protein, heat-shock proteins, and Bcl-2 form a complex in mitochondria and modulate mitochondria function and apoptosis in N2a cells. Mech Ageing Dev2009; 130: 592–601.
42.
Del PreteDSuskiJMOulesB, et al.Localization and processing of the amyloid-beta protein precursor in mitochondria-associated membranes. J Alzheimers Dis2017; 55: 1549–1570.
43.
BhattacharyyaRBlackSELotlikarMS, et al.Axonal generation of amyloid-beta from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes. Cell Rep2021; 35: 109134.
44.
PeraMLarreaDGuardia-LaguartaC, et al.Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer disease. EMBO J2017; 36: 3356–3371.
45.
PavlovPFWiehagerBSakaiJ, et al.Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J2011; 25: 78–88.
46.
Area-GomezEDel Carmen Lara CastilloMTambiniMD, et al.Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J2012; 31: 4106–4123.
47.
ThinakaranGKooEH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem2008; 283: 29615–29619.
48.
HaassCKaetherCThinakaranG, et al.Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med2012; 2: a006270.
49.
LaiASisodiaSSTrowbridgeIS. Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. J Biol Chem1995; 270: 3565–3573.
50.
Marquez-SterlingNRLoACSisodiaSS, et al.Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci1997; 17: 140–151.
51.
HaassCSchlossmacherMGHungAY, et al.Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature1992; 359: 322–325.
52.
WilliamsonRLLaulagnierKMirandaAM, et al.Disruption of amyloid precursor protein ubiquitination selectively increases amyloid beta (Abeta) 40 levels via presenilin 2-mediated cleavage. J Biol Chem2017; 292: 19873–19889.
53.
BosettiFBrizziFBarogiS, et al.Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging2002; 23: 371–376.
54.
CardosoSMProencaMTSantosS, et al.Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging2004; 25: 105–110.
55.
FlannaganKStopperanJAHaugerBM, et al.Cell type and sex specific mitochondrial phenotypes in iPSC derived models of Alzheimer's disease. Front Mol Neurosci2023; 16: 1201015.
56.
ParkerWDJr.ParksJK. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology1995; 45: 482–486.
57.
SwerdlowRHParksJKCassarinoDS, et al.Cybrids in Alzheimer's disease: a cellular model of the disease?Neurology1997; 49: 918–925.
58.
WilkinsHMKoppelSJBothwellR, et al.Platelet cytochrome oxidase and citrate synthase activities in APOE epsilon4 carrier and non-carrier Alzheimer's disease patients. Redox Biol2017; 12: 828–832.
59.
Area-GomezESchonEA. On the pathogenesis of Alzheimer's disease: the MAM hypothesis. FASEB J2017; 31: 864–867.
60.
KleinHUTrumpffCYangHS, et al.Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer's disease brain. Mol Neurodegener2021; 16: 75.
61.
ZhangYLiuXWigginsKL, et al.Association of mitochondrial DNA copy number with brain MRI markers and cognitive function: a meta-analysis of community-based cohorts. Neurology2023; 100: e1930–e1943.
62.
XiongWMaZAnD, et al.Mitofusin 2 participates in mitophagy and mitochondrial fusion against angiotensin II-induced cardiomyocyte injury. Front Physiol2019; 10: 411.
63.
Del PreteDRiceRCRajadhyakshaAM, et al.Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration. J Biol Chem2016; 291: 17209–17227.
64.
HaenigCAtiasNTaylorAK, et al.Interactome mapping provides a network of neurodegenerative disease proteins and uncovers widespread protein aggregation in affected brains. Cell Rep2020; 32: 108050.
65.
AndreuxPABlanco-BoseWRyuD, et al.The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab2019; 1: 595–603.
66.
HouXWatzlawikJOCookC, et al.Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology. Alzheimers Dement2021; 17: 417–430.
67.
HuYLiXCWangZH, et al.Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget2016; 7: 17356–17368.
68.
ManczakMKandimallaRYinX, et al.Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease. Hum Mol Genet2018; 27: 1332–1342.
69.
Martin-MaestroPGarginiRSproulA, et al.Mitophagy failure in fibroblasts and iPSC-derived neurons of Alzheimer's disease-associated presenilin 1 mutation. Front Mol Neurosci2017; 10: 291.
70.
MaryAEysertFCheclerF, et al.Mitophagy in Alzheimer's disease: molecular defects and therapeutic approaches. Mol Psychiatry2023; 28: 202–216.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
